Description

Zalutumumab CAS NO 667901-13-5 is a recombinant human monoclonal antibody designed to target the epidermal growth factor receptor (EGFR). This product matters for its specific antagonistic activity against EGFR, a key pathway in cellular proliferation and survival. It is primarily needed by pharmaceutical research and development teams, biotech companies, and academic institutions engaged in oncology research, particularly for investigating therapeutic strategies against EGFR-expressing cancers.

Application

• Oncology Research: A critical reagent for in vitro and in vivo studies targeting EGFR-positive tumors, such as head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC).
• Mechanism of Action Studies: Used to investigate the inhibition of EGFR signaling, downstream effects on cell cycle arrest, and induction of apoptosis.
• Therapeutic Antibody Development: Serves as a reference standard or a lead compound in the development and screening of next-generation biologic therapeutics.
• Combination Therapy Research: Employed in preclinical models to evaluate synergistic effects with chemotherapy, radiation, or other targeted agents.
• Diagnostic Assay Development: Can be utilized in the development of companion diagnostic tests to identify patient populations likely to respond to anti-EGFR therapies.
• Biomarker Validation: Used in research to validate EGFR as a predictive or prognostic biomarker in various cancer types.

Basic Information

Product Name	Zalutumumab
CAS No.	667901-13-5
Molecular Formula	C6440H9916N1700O2016S46
Molecular Weight	Approx. 145 kDa
Synonyms	HuMax-EGFr; 2F8 Monoclonal Antibody; Anti-EGFR Monoclonal Antibody 2F8; Recombinant Human Anti-EGFR IgG1κ Antibody; UNII-6Z7C1CU36I; Zalutumumab (INN); Zalutumumab (USAN)
EINECS	Contact for details

Quality Control

Our Zalutumumab is produced and tested under stringent quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, potency, and safety, aligning with ICH Q6B guidelines for biotechnological products. Comprehensive characterization includes tests for purity (SEC-HPLC, CE-SDS), potency (cell-based bioassay), and structural integrity (mass spectrometry, peptide mapping). A detailed Certificate of Analysis (COA) is provided with each shipment.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store at -20°C to -80°C. Avoid repeated freeze-thaw cycles. The product is hygroscopic (moisture-sensitive). Aliquot into working volumes upon first thaw to maintain stability.

Specification

Item	Specification
Appearance	Clear to slightly opalescent, colorless to pale yellow solution
Identification (SEC-HPLC)	Retention time corresponds to reference standard
Purity (SEC-HPLC)	≥ 95.0% Monomer
Purity (CE-SDS, reduced)	Heavy Chain & Light Chain present; ≥ 90.0% Purity
Protein Content (A280)	1.0 ± 0.2 mg/mL (or as per COA)
Potency (Cell-based ELISA)	EC50 within defined range of reference standard
Endotoxin (LAL)	< 1.0 EU/mg
pH	6.5 - 7.5

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.